LCDActive
MolDX: HLA-DQB1*06:02 Testing for Narcolepsy
L36551
Effective: August 21, 2025
Updated: December 31, 2025
Policy Summary
HLA-DQB1*06:02 typing (CPT 81383) for narcolepsy is considered experimental/investigational/unproven and is not covered for any population. Evidence indicates the allele is associated with increased risk but is insufficient to confirm, exclude, or quantify narcolepsy risk and has no demonstrated clinical utility for diagnosis or management.
Coverage Criteria Preview
Key requirements from the full policy
"HLA-DQB1*06:02 typing (CPT 81383) for the diagnosis or management of narcolepsy is considered experimental, investigational, or unproven and is not covered for any population."
Sign up to see full coverage criteria, indications, and limitations.